It is not the first immunotherapy drug available for advanced lung cancer - pembrolizumab was approved for use in December 2016 - but nivolumab hit the headlines during AA Gill's final weeks.

The FDA on Thursday expanded the U.S.-approved indications for Bristol-Myers ... Accordingly, the anti-PD1 agent, also known ...

The failure of the KEYNOTE-240 raised the prospect of Keytruda being stripped of its indication ... the FDA advisory committee voted that its Opdivo (nivolumab) therapy should lose its approval ...

After five years, combination treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab ... uses the body’s immune system to ...

Last week, Bristol Myers BMY obtained FDA approval for a label expansion of its blockbuster immuno oncology drug Opdivo (nivolumab ... for various oncology indications, and label expansion ...